GKOS

Glaukos Corporation (GKOS) shares have gained 36.8% over six months, outperforming its industry, driven by strong Q2 results with 50% revenue growth to $185.6 million, successful commercial expansion of Epioxa for keratoconus treatment, positive clinical data for iDose TR, and pipeline advances including a new retinal disease licensing agreement. The company raised its 2026 revenue guidance to $680-$700 million.

Glaukos Corporation announced a licensing agreement with RevOpsis Therapeutics to develop RO-104, a first-in-class tri-specific biologic for retinal diseases, and gained exclusive access to the RevMod platform for up to four additional retinal biologic candidates. Despite the strategic expansion, GKOS stock declined 6.3% following the announcement, though it has gained 42.8% year-to-date.